GlassScriptPhysician profile
Deborah A Sculco
NPI 1013910660
$4,743.72
in general payments reported to CMS, 2019-2025
27 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $513 · 2021: $732 · 2022: $605 · 2023: $576 · 2024: $518 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.07 |
| Education | $179.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,521.41 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Regeneron Healthcare Solutions, INC. | $589.86 | 2021-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $454.46 | 2019-2025 | Tagrisso, Datroway, Imfinzi |
| Janssen Biotech, INC. | $254.28 | 2019-2025 | Rybrevant, Carvykti, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $202.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.45 | 2019-2022 | |
| Genentech USA, INC. | $159.97 | 2019-2025 | Tecentriq Hybreza |
| Amgen INC. | $146.82 | 2019-2020 | |
| Exelixis INC. | $145.38 | 2019-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $137.48 | 2019 | |
| Incyte Corporation | $118.73 | 2019-2020 | |
| Epizyme, INC. | $99.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Astellas Pharma US INC | $99.95 | 2023 | |
| Lilly USA, LLC | $99.26 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $97.86 | 2019-2025 | |
| Seagen INC. | $61.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $58.04 | 2019 | |
| Pfizer INC. | $48.10 | 2019 | |
| Celgene Corporation | $31.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $24.19 | 2019 | |
| Array Biopharma INC | $22.96 | 2019 | |
| Genzyme Corporation | $22.10 | 2021 | |
| Cti Biopharma Corp. | $20.83 | 2023 | Vonjo |
| Taiho Oncology, INC. | $19.69 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.62 | 2023 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Sculco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.